ITX5061 is a small molecule investigated primarily as an entry inhibitor for hepatitis C virus (HCV), targeting the host cell receptor claudin-1 (CLDN1) to prevent viral entry into hepatocytes. It has shown potential in preventing HCV reinfection in liver transplant patients and treating chronic liver diseases associated with HCV. Research also explores its broader applications in modulating cellular signaling pathways, including roles in immune responses and potential antiviral effects against other pathogens. Studies are ongoing to evaluate its efficacy, safety, and clinical utility in infectious and liver diseases.